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ABSTRACT 
 
Oncology has benefited from an increasingly growing number of groundbreaking 
innovations over the last decade. Targeted therapies, biotherapies, and the most recent 
immunotherapies all contribute to increase the number of therapeutic options for 
cancer patients. Consequently, substantial improvements in clinical outcomes for some 
disease with dismal prognosis such as lung carcinoma or melanoma have been 
achieved. Of note, the latest innovations in targeted therapies or biotherapies do not 
preclude the use of standard cytotoxic agents, mostly used in combination. Importantly, 
and despite the rise of bioguided (a.k.a. precision) medicine, the administration of 
chemotherapeutic agents still relies on the maximum tolerated drug (MTD) paradigm, 
a concept inherited from theories conceptualized nearly half a century ago. Alternative 
dosing schedules such as metronomic regimens, based upon the repeated and regular 
administration of low doses of chemotherapeutic drugs, have emerged as possible 
strategies to improve response rates while reducing toxicities. The recent changes in 
paradigm in the way we theorize cancer biology and evolution, metastatic spreading 
and tumor ecology, alongside the recent advances in the field of immunotherapy, have 
considerably strengthened the interest for metronomic approaches. This paper aims at 
reviewing the recent evolutions in the field of theoretical biology of cancer and 
computational oncology, with a focus on the consequences these changes have on the 
way we administer chemotherapy.  In particular, a step towards developing adaptive 
dosing should help to further optimize the efficacy of metronomic therapy.  There is a 
rising trend to establish personalized medicine in oncology.  Developing extensive bio-
guided strategies for decision-making in the choice of drugs to be administered is now 
a common practice at the bedside. Similarly, developing extensive model-guided 
strategies for decision-making in refining dosing and scheduling should be undertaken 
to achieve precision medicine in oncology. 
 
 
 
INTRODUCTION 
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Innovative technologies have dramatically changed the way we treat cancer. From 
crude surgery for centuries, to the introduction of radiotherapy in the 1930’s and that 
of chemotherapy in the 1950’s [1], we can now envision the development of 
personalized treatments for cancer patients, thanks to the advances made in biology, 
chemistry, physics, mathematics and engineering. Immune checkpoint inhibitors, anti-
angiogenics and targeted therapies have already entered the clinic with various level of 
success, and innovative technologies in imaging, PK/PD modeling and the omics are 
helping clinicians in their decision making on a daily basis. Yet, chemotherapy is still 
administered today almost the exact same way it was fifty years ago. Why is that? 
Here we will try to address this question by looking back at the early theoretical 
concepts that led to the development and widespread use of what is now called 
“conventional chemotherapy” – i.e. the administration of chemotherapy at or close to 
the maximum tolerated dose (MTD), with drug-free breaks in between cures to allow 
for the patient to recover from the treatment-related toxicities. We will explain the 
limitations of these early theoretical and mathematical models and discuss ways they 
can be improved to better take into account the complexity and rapid evolution of 
tumors and ultimately optimize treatment efficacy. This will lead us to present 
innovative theoretical models that support alternative ways of administering 
chemotherapy. These include metronomic chemotherapy [2–4] – i.e. the frequent 
administration of chemotherapeutic drugs at relatively low, non-toxic doses, without 
prolonged drug-free break – and adaptive therapy [5,6] – i.e. modulating the dose and 
frequency of chemotherapy administrations in order to maintain a constant tumor 
volume. Metronomic chemotherapy is expected to bring substantial benefit over 
existing MTD regimen by interfering with novel targets at the tumor level or the tumor 
micro-environment level (Figure 1).  In many respects, developing metronomic 
chemotherapy could pave the way for implementing computational oncology at 
bedside, because optimizing metronomic regimen should only be achieved thanks to 
modeling support. 
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Historical concepts 
Fifty years ago, Skipper, Schabel and Wilcox were the first to introduce theoretical 
concepts for the optimal design of chemotherapy schedules [7] . Based on 
experimental studies involving L1210 leukemic cells — which exhibit exponential 
growth when left untreated —, they introduced and demonstrated the log-kill effect for 
several cytotoxic agents, including 6-mercaptopurine, 5-fluoruracil and vinblastine [7]. 
This principle, based on an analogy with the law of mass action for kinetic reactions in 
chemistry, states that exposure to a given amount of drug kills a constant fraction of a 
cancer cell population, hence reducing it of a constant amount in logarithmic scale 
(Figure 2). For instance, if a drug has a one log-kill effect, then it will reduce a 
population of 10
6
 cells to 10
5
 cells and a population of 10
2
 cells to 10
1
 cells. Further on, 
based on their experimental work that demonstrated that the presence of as little as one 
single leukemic cell was sufficient to lead to the host death, they argued that the goal 
of the therapy should be to achieve complete cure of the disease, i.e. eradication of all 
malignant cells. In this context, they demonstrated that a large-dose/short time (single 
administration) schedule was superior to a chronic (daily) low-dose schedule (with 
similar or larger total dose) [8]. However, when this view (that was involved in the 
calculation of the number of cycles required for cure) was applied to the adjuvant 
systemic treatment of micrometastases (for breast cancer for instance), it did not lead 
to the expected results [9]. Two major criticisms were addressed to the work of 
Skipper et al.: 1) they considered a homogeneously sensitive population of cancer cells 
(i.e. no resistance was explicitly taken into account) and 2) the experimental system 
they employed was limited to a single leukemic cell line and their conclusions might 
not extend to solid tumors.  
Regarding point 1), substantial efforts in the modeling of resistance to cytotoxic agents 
have been provided by the work of Goldie and Coldman [10]. The Goldie-Coldman 
model states that mutation rates towards resistance are relatively high within a 
population of tumor cells and that mutations develop spontaneously during the natural 
course of the disease (innate resistance). This implies that the treatment should start as 
soon as possible in order to avoid the natural tumor progression leading to the presence 
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of more resistant cells. It also implies that if several drugs are to be administered and 
cannot be given simultaneously for toxicity constraints, they should be delivered 
alternatively in order to avoid resistance to drug B to develop during therapy with drug 
A. However, predictions of this model were ruled out by several trials, in breast cancer 
patients for instance, where strategies that delay therapy or did not respect strict 
alternation of combination regimen were proven to perform at least as well as the 
Goldie-Coldman recommended strategy [11]. One of the main hypotheses underlying 
the Goldie-Coldman model is the concept of absolute resistance, which is discussable. 
Indeed, there is some evidence that tumors can exhibit various levels of relative drug 
resistance [12].  
In the 1960’s, thorough study of tumor kinetics led to the realization that the specific 
tumor growth rate for solid tumors, instead of being constant (exponential growth), 
was rather a decreasing function of the volume, provided tumor growth is observed 
long enough [13–15]. In mathematical terms, tumor growth can be formalized by 
means of the following differential equation 
 
��
��
= � � �  (1)  
 
which equates the (infinitesimal) increase in tumor volume (size) per unit of time on 
the left hand side and a function of the volume on the right hand side (the growth rate). 
In the expression above, function f is the specific growth rate that was evidenced as 
being decreasing, first in animal studies by growth curve analysis [16,17] followed by 
clinical investigations. The latter were either directly based on patient data such as 
direct cells counts in IgG multiple myeloma patients [18] or mammographic 
measurements of breast tumors [13]; or indirectly from survival data of untreated 
patients [19] or the distribution of tumor size in the patient population [20]. More 
specifically, investigators demonstrated that the growth curve patterns could be well 
described by several structural expressions, the most famous (and employed) being the 
Gompertz law (f(V) = α – βln(V)))  [16,19,21–23]. This expression is not the only one 
able to describe the empirical data and other models such as the power law (f(V) =  
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aV
γ-1
) can do as good as the Gompertz, while their etiology might be better grounded 
(fractional dimensional of the vasculature) [17,20,23,24]. We refer to [23] for a recent 
review of the descriptive and predictive properties of these models for experimental 
data.  
In the 1970’s, L. Norton and R. Simon revisited the Skipper-Schabel-Wilcox log-kill 
hypothesis, in order to extend it to growing tumors with non-constant specific growth 
rate [25]. They suggested that since chemotherapy is mostly based on anti-mitotic 
agents, it should only be active against these cells that are actively proliferating, i.e. 
precisely the ones that contribute to the volume increase in equation (1) [25]. 
Moreover, the current view of the effect of chemotherapy (log-kill) was in 
contradiction with clinical observations such as: a) the effect on small tumors in an 
adjuvant setting was not as pronounced as expected and b) decreased sensitivity to 
therapy was observed also for very large tumors. Instead of a killing term proportional 
to the volume of the tumor, they proposed a killing term proportional to the tumor 
growth rate, i.e.:  
��
��
= � � �(1− � � ) 
 
They demonstrated that their model was consistent with clinical observations, able to 
fit preclinical experiments and was superior to the log-kill model in predicting the 
future course of an experimental treated growth curve from a few initial measurements 
[25]. This model has profound clinical implications. First, it predicts a superiority of 
densified dosing regimens. Indeed, if less inter-cycle time is allowed to the tumor to 
regrow, it reaches a smaller size at the beginning of the next cycle, thus a larger 
growth rate (Gompertzian growth) and consequently a larger amount of cells killed by 
the drug [25]. This prediction was confirmed by clinical trials that densified 
administration drug schedules from every 21 days to every 14 days and showed benefit 
of applying the second regimen [26]. Second, extending these concepts to drug 
combinations, the Norton-Simon model advocates for sequential administration of the 
drugs (in order to densify the treatment for each drug separately), as opposed to the 
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strict alternation supported by the Goldie-Coldman model. Clinical trials (for the 
treatment of breast cancer for instance) again confirmed this prediction of the Norton-
Simon model [27,28]. This example demonstrates how rational thinking and 
mathematical methods, based on phenomenological theories, can help to successfully 
guide clinical trials [29,30]. Under the Norton-Simon hypothesis, larger absolute kill 
of cancer cells resulting from early chemotherapy, as opposed to late chemotherapy, 
might be counter-balanced by faster regrowth due to high growth rates of small tumors 
(see Figure 2, right panel), thus leading to similar overall survival in both cases, 
despite significantly different times to relapse [31].  
 
Modern cancer biology 
During the early phases of the development of chemotherapy, the ultimate goal of 
therapy was always complete cure from the disease. As stated by Skipper et al.: “(...) it 
appears that high-level, short-term schedules offer considerably greater potential for 
obtaining “cures”” [7]. Interestingly, even if these investigators were pleading for this 
option, they already had noticed that this might not be the best strategy to achieve best 
long-term control of the disease. Indeed, the previous quote continues with “This 
preference does not necessarily hold with regards to achieving maximum increase in 
life span of animals which die in spite of therapy”. Since several years, there is an 
increasing trend towards a paradigm shift in clinical oncology: in view of the failure to 
cure patients using conventional approaches, investigators proposed to change the goal 
of therapy from complete eradication of the tumor to a long-term management of the 
disease [6]. This suggests that instead of waiting for “magic bullets” that would 
provide an absolute and complete solution, one might instead look into optimization of 
already existing therapeutic tools. In order to improve current cancer treatments, 
historical concepts need to be revised to better take into account the complexity of the 
disease, including the impact of the tumor microenvironment (e.g. vasculature and 
immune system) and clonal heterogeneity on the efficacy of chemotherapy protocols. 
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Tumor heterogeneity and (epi)-genetic resistances 
In a very elegant, simple and conceptually powerful theoretical study, Hahnfeldt, 
Folkman and Hlatky re-analyzed the problem of dose repartition in light of tumor 
heterogeneity [32]. They considered two subpopulations of cancer cells with two 
distinct sensitivities to a given drug, with transition rates between the two. Importantly, 
the transition rate from the less sensitive population to the most sensitive one was 
assumed to be positive, thus allowing for a resensitization effect. Under their minimal 
framework that allows to perform explicit computations, they demonstrated that more 
regularly spaced dosing of the drug yields better final tumor reduction when compared 
to irregular spacing, for both single and multiple cycles therapies. Eventually, based on 
the assumption that the endothelium is more subject to resensitization than the tumor 
compartment, they also proposed their model as an explanation for the anti-angiogenic 
basis of metronomic chemotherapy [33]. Along the same lines (i.e. heterogeneous 
population of cancer cells composed of both resistant and sensitive cells that can 
switch phenotypes), and adding stochasticity in the dynamics (Markov Chain process), 
Liao et al. recently developed a graphical tool, termed metronogram, which provides 
indications on how to adapt the period between subsequent administrations of the drug 
in order to maintain anti-tumor efficacy [34]. 
Inspired by the example of invasive species in ecology and the use of pesticides, a 
situation where complete eradication is usually impossible due to high phenotypic 
diversity that leaves resistant individuals after intervention, R. Gatenby proposes to see 
a tumor as an ecosystem ruled by evolutionary laws [6]. In this context, high dose 
chemotherapy might have the deleterious effect of selecting for the most resistant cells, 
by eliminating the sensitive competitors. On the other hand, a low-dose continuous 
therapy, by keeping a positive amount of sensitive cells, might provide a better long-
term control of the total population [6]. In a study using both mathematical and 
experimental approaches, Gatenby and colleagues further developed this concept and 
introduced the idea of adaptive therapy. It consists in modulating the dose and 
frequency of therapeutic administrations in order to maintain a constant tumor volume, 
as opposed to the conventional approach that administers a fixed dosing regimen 
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repeated over several cycles [5]. Although performed on only one (ovarian) cancer cell 
line and resulting in a (possibly toxic) larger total dose, the adaptive schedule was 
found to be superior to the standard MTD one, yielding excellent long-term 
management of the tumor mass. 
Applying the same evolutionary concepts to population dynamics of cancer cells, 
Clairambault et al. developed a modeling framework that revisited the concepts 
underlying the Delbrück-Luria/Goldie-Coldman model of spontaneous development of 
resistance [35]. In their work, they made two major hypotheses: 1) reversible, drug-
induced (rather than irreversible and spontaneous) development of resistance, based on 
a recent experimental study  and 2) varying levels of resistance (instead of the classic 
sensitive/resistant dichotomy). Point 2) was elegantly formalized in mathematical 
terms within the context of structured evolutionary population dynamics, by means of 
one (or more) continuous variable representing a phenotyping trait [36,37]. Full 
implications of these recent studies in terms of optimal scheduling have not yet been 
published but will probably generate non-trivial insights on optimal administration 
schedules emerging from the complex dynamics due to tumor heterogeneity. 
Anti-angiogenesis 
Metronomic chemotherapy was initially developed to potentiate the anti-angiogenic 
properties of chemotherapeutic drugs [33,38]. This target switch has important 
implications in terms of optimal scheduling for the delivery of a cytotoxic agent. In 
1999, Hahnfeldt et al. derived a biologically-based (yet technically simple) 
mathematical model for tumor growth under endogenous angiogenic signaling that 
was able to describe the effect of several anti-angiogenic molecules [39]. Based on this 
model, d’Onofrio and Gandolfi studied the effect of scheduling variations and obtained 
that a drug targeting the vasculature would have a better effect if administered more 
frequently at lower doses (assuming constant total dose) [40]. When the drug effect 
was further assumed to depend on the vascular density, a nontrivial optimal 
metronomic inter-administration time was found [41]. Interestingly, metronomic 
scheduling additionally exhibited enhanced robustness towards noise-induced 
transitions (i.e. escape from therapeutic control) in response to stochasticity in the 
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clearance rate [42]. Going further in the implications of the Hahnfeldt model, 
Ledzewicz and Schättler performed a full optimal control analysis for theoretical 
optimization of the scheduling of a drug with anti-angiogenic properties [43]. 
Interestingly, they found that the optimal control, instead of having a bang-bang 
expression (constant full-dose sections separated by breaks – i.e. conventional 
chemotherapy), could exhibit singular arc portions where the drug is administered at a 
lower dose than the MTD, with varying rates. This is the expression in mathematical 
terms of the concept of a biologically optimal dose, which might differ from the MTD.  
Recently, mathematical models specifically tailored for the analysis of the anti-
angiogenic effect of metronomic chemotherapy in various concrete clinical settings 
were introduced [44–46]. All these rely on the same assumptions: a) chemotherapy has 
an anti-angiogenic effect by killing endothelial cells in addition to its cytotoxic effect 
on cancer cells [38,47], b) cancer cells develop resistance whereas endothelial cells do 
not (due to larger genetic stability) and c) drug action is stronger on endothelial cells 
than on tumor cells [47]. Using realistic pharmacokinetic models and an interface 
model for description of the efficacy from the concentration of the drug in the central 
compartment, MTD and metronomic schedules were compared in silico for the 
administration of docetaxel [44] or etoposide [45]. In the docetaxel study, the effect on 
metastatic dissemination was also taken into account. Interestingly, the simulations 
revealed a long-term beneficial effect of the metronomic regimens, despite an initial 
superiority of the MTD schedule (Figure 3). Indeed, examination of the dynamic 
properties of the system revealed that, under the MTD schedule, the fast endothelial 
dynamics generated sharp relapses during the drug-free breaks that ultimately led to 
global relapse due to resistance (Figure 3). On the other hand, the metronomic regimen 
ensured a more stable action on the endothelium that ultimately led to oxygen and 
nutrient deprivation of the tumor. Of note, when the daily dose of the metronomic 
schedule was too low (e.g. 8 mg/day), the treatment could not suppress the growth of 
the tumor, which escaped therapy. This result emphasizes the existence of a minimal 
dosing schedule (minimally effective dose) that could be computed using the 
mathematical model, provided it is properly calibrated on patient data. This dose 
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depends on specific model parameters that might vary among patients. It is important 
to note that the determination of biologically optimal dose requires reliable biomarkers. 
Several markers of response to metronomic chemotherapy have been suggested over 
the years, such as plasma levels of endogenous angiogenesis inhibitor 
thrombospondin-1 and the number and viability of circulating endothelial cells [48]. 
However, correlations between these biomarkers and study endpoints were rare and 
variable, making them unsuitable for model parameterization.  
Similar mathematical model for anti-tumor efficacy can be complemented with a 
model for hematologic toxicity (i.e., neutrophil counts), thus opening the way to 
developing more sophisticated constraint-models able to calculate optimal dosing for 
maximal efficacy while respecting clinical requirements on a certain level of 
acceptable hematological toxicities [49].  
In the clinic, most cancer-related deaths are not due to the primary tumor, but rather to 
the metastases [50]. To address the issue of treatment on a population of tumors (rather 
than a single tumor), as well as the effect on the dissemination process, Benzekry and 
Hahnfeldt [51] defined an optimal control problem written for an organism-scale 
model of metastatic development. Although complete mathematical analysis was too 
complicated to be achieved, they could perform a simulation study and found that the 
overall efficacy of cytotoxic agents, either alone or in combination with anti-
angiogenic drugs, was generally maximized when employing a metronomic schedule 
rather than the MTD. Interestingly, in some instances (e.g. values of the parameters, 
objective function considered), differences in the best strategy occurred between the 
treatment of the (isolated) primary tumor and the treatment of the (systemic) cancer at 
the organism scale. These theoretical predictions were independently confirmed in 
recent pre-clinical studies using mouse models of spontaneous metastases [52]. 
Role of the immune system 
The role of the immune system in cancer biology and response to treatment is 
becoming increasingly recognized and has major therapeutic implications [53]. The 
genetic and cellular alterations that define cancer provide the immune system with the 
means to generate T cell responses that recognize and eradicate cancer cells. However, 
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elimination of cancer by T cells has to be balanced with the recognition of non-self 
and the prevention of auto-immunity. Identification of T cell inhibitory signals induced 
by cancer cells, including PD-L1, has led to the development of a new class of cancer 
immunotherapy that specifically hinders immune effector cell inhibition, 
reinvigorating and potentially expanding preexisting anticancer immune responses. 
The presence of suppressive factors in the tumor microenvironment may explain the 
limited activity observed with previous immune-based therapies and why these 
therapies may be more effective in combination with agents that target other steps of 
the cycle. Recent clinical data confirm that cancer immunotherapy is likely to become 
a key part of the clinical management of cancer and numerous innovative drugs are yet 
to come [54]. Elsewhere, several pre-clinical and clinical studies have shown that 
changing the administration schedule from MTD to a metronomic protocol 
considerably impacts the effects of chemotherapy on the immune system, switching 
from immunosuppression to immunostimulation [3]. 
Recently, Ledzewicz and Schättler proposed a model integrating three components for 
the effect of chemotherapy: a direct cytotoxic effect on cancer cells, an anti-angiogenic 
effect and an immune-stimulatory effect [55]. They mathematically investigated the 
dynamics of the resulting system under constant infusion therapy. However no study 
of the effect of the scheduling has yet been performed in this model or validated in 
vivo. Using ectotopic glioma mouse models, Doloff and Waxman demonstrated that a 
metronomic cyclophosphamide regimen, rather than exerting anti-angiogenic effects, 
elicited anti-tumor innate immunity, including recruitment of macrophages, dendritic 
and NK cells [56]. Going further, the same group then reported a schedule dependence 
of this anti-tumor innate immune effect of metronomic chemotherapy, with significant 
differences in growth curves for cyclophosphamide administered either every 3 days 
or every six days (the classical metronomic regimen [38]), while total exposure was 
kept constant [57]. Their results highlight the potentiality of model-driven 
optimization of the scheduling in order to find non-trivial optima for dose and 
frequency of administration.  
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In a theoretical study, I. Kareva proposed a model for interactions between cancer 
stem cells, non-stem cancer cells , and cytotoxic lymphocytes [58]. By suggesting that 
the non-stem cancer cells might provide a protective shield to the cancer stem cells, 
she developed a mechanistic rationale for the use of metronomic chemotherapy: 
frequent administration of a cytotoxic drug at low dose might provide a continuous 
pealing of the non-stem cancer cells layers protecting the cancer stem cells, while not 
depleting too strongly the lymphocyte population, therefore restoring anti- cancer stem 
cells immunity. Of note, the immunomodulatory properties of metronomic 
chemotherapy may vary according to the cytotoxics used [59]. Regulatory T cells for 
instance may be targeted using metronomic temozolomide or cyclophosphamide, 
myeloid-derived suppressor cells can be modulated using metronomic gemcitabine and 
5-fluorouracil, innate immune response can be activated by metronomic temozolomide 
while maturation of dendritic cells can be induced by metronomic vinblastine [4]. 
Future computational models will need to take into account these specificities in order 
to develop optimal metronomic protocols. 
 
Era of  Metronomic  2.0. : are we there yet? 
 
Deciphering the mechanisms responsible for the antitumor activity of metronomic 
regimens is particularly challenging because of the overlap between anti-angiogenic, 
immune-stimulatory and cytotoxic effects. Importantly, each drug has its own 
mechanism of action, multiple drugs can be combined, and each drug can be given 
following a near infinite number of combinations depending on dose, frequency and 
duration of administration. As a consequence, standard empirical designs to test 
metronomic regimens are unlikely to identify the optimal combination between  drugs, 
dosing and scheduling, to achieve the best efficacy in cancer patients. In this respect, 
mathematical modeling can be regarded as a critical and powerful new tool in 
decision-making, provided that suitable models are made available and validated. Such 
models will allow testing numerous hypotheses in silico so as to identify, in a cost-, 
time- and ethically-effective manner, the best regimen among countless possibilities.  
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Implementation of computational oncology into metronomic can be achieved using 
mechanistic models. Those models take into account all the components related to 
tumor biology, plus the intrinsic mechanisms of action of the drugs, thus leading to a 
multi-scale model encapsulating all the items to be taken into account to achieve some 
antitumor efficacy eventually. Another strategy is to develop phenomenological 
models, aiming at describing, with no or little mechanistic basis, the impact of 
metronomic regimen, mostly on a simplified PK/PD basis, with some critical features 
such as integration of a resistance component. Such a model has been recently 
proposed by Faivre et al. for the administration of temozolomide [45], and used in 
silico as a tool to compare metronomic and MTD administrations, thus predicting the 
respective efficacy of these regimens. The same model has been adapted and extended 
to oral vinorelbine, another cytotoxic drug frequently administered following 
metronomic schedules [46]. In this study, the model was used to identify an optimal 
metronomic protocol for lung cancer patients, based upon clinical data already 
published in patients with solid tumors. In silico simulations suggested that an 
alternative 60-30-60 mg dosing given on a D1-D2-D4 basis should lead to higher 
efficacy with a good tolerance as compared with all other metronomic regimens tested 
thus far. Of note, such contra-intuitive schedule could not have been identified simply 
by analyzing the results of the dozen of phase I or phase II trials conducted with 
metronomic vinorelbine. Finally, this kind of simplified, phenomenological model was 
used to drive metronomic gemcitabine in a non-clinical study [60].  Data from tumor-
bearing mice showed outstanding response in a resistant model of neuroblastoma, 
following a metronomic scheduling (i.e., 1 mg/kg/d over 28 days) identified by a 
mathematical model among a variety of possible combinations between doses, 
frequency and duration [61,62]. This result highlights how model-driven metronomic 
can improve the efficacy of chemotherapy indeed. The converging advances in the 
fields of mathematics, tumor biology and pharmacology, advocate for the development 
of modeling supports (either mechanistic or merely descriptive). In particular, beyond 
the very concept of metronomic administration, refining dosing and scheduling 
through adaptive strategies is a challenging task requiring specific modeling resources. 
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For instance, inter-patient variability affecting pharmacodynamic determinants (i.e. 
target expression or target mutation, genetic or molecular dysregulations on 
downstream signaling pathways) or pharmacokinetic determinants (i.e., drug 
metabolizing enzymes, membrane transporters, upstream transcription factors 
regulating both enzymes and transporters expression) can be major causes for 
treatment failure upon standard dosing [63]. In this respect, developing global tools 
encompassing PK/PD models for guiding metronomic administration, plus possible 
pharmacogenomic and pharmacogenetic determinants to be used as covariates for 
further tailor dosing,  should help to improve clinical outcome. Only a few studies 
have presented such model-driven dosing strategies that take into account individual 
factors of variability such as genetic polymorphisms affecting PK/PD relationships.  
Yet, appealing results in terms of prediction or  improvement of the clinical outcome 
in patients with cancer treated with standard dosing have been reported [64, 65].  In 
addition to tailored dosing, modeling pharmacogenomic determinant should help to 
forecast treatment efficacy, thus potentially helping the decision-making to treat, or 
not, certain patients. For instance,  genetic profiling of circulating tumor and invasive 
cells in patients with pancreatic cancer and development of a dedicated model, allowed 
predicting effective and ineffective chemotherapeutic agents. In this blind study, 
clinical outcome proved to match initial model predictions, thus suggesting that a 
prospective use of the model for decision-making could have avoided ineffective 
treatments [66].    To what extent genetic polymorphisms could be considered as 
biomarkers when performing metronomic administration remain to be fully elucidated 
before being implemented in dedicated models.  For instance, using low doses of 
cytotoxics is usually less likely to saturate enzymatic systems or active transporters, 
thus smothering the impact of  inter-patient variability  in terms of  decreased 
expression or activity  in drug transport or disposition in the body [67].  Conversely, 
ultra-metabolizer patients could become  more rapidly prone to treatment failure by an 
increased liver clearance [68].  Further prospective studies are warranted to test all 
these model-based strategies with metronomic approaches, since inter-patient 
variability is a challenging issue that remains largely underestimated.  
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In this context, metronomic  illustrates how the time for trial and error practices is now 
over, and calls for developing computationally-driven regimens as a means to optimize 
anticancer therapies in the 21
st
 century.  
Conclusion 
 Modern cancer biology has accumulated a large amount of knowledge about 
the various players involved in neoplasia and their interactions. Consequently, it 
becomes more and more difficult to determine the outcome of therapeutic intervention 
using cytotoxic agents (in monotherapy or in combination with other drugs) using 
rational thinking alone. In this regard, mathematical and computational models offer 
powerful tools that are currently under-utilized but could help in: 1) conceptualizing 
our theoretical thinking of the disease and the dynamics of therapeutic interventions, 
2) identifying critical variables and parameters, 3) potentiating the analysis of 
available data and/or patient biomarkers and 4) simulating the outcome of complex 
situations. Under these lines of reasoning they could offer invaluable help to: 1) test a 
wide range of possibilities in silico for the design of anti-cancer drug regimens before 
validation of these innovative protocols in animal models and 2) personalize the 
dosing of anti-cancer agents, using patient-specific model parameters informed by 
biomarkers. 
Future efforts are needed both in terms of precisely defining the essential dynamics to 
be modeled for a given pathology, clarifying the objectives to be optimized, and 
identifying reliable biomarkers and their connections to model parameters. 
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FIGURES LEGENDS 
 
 
Figure1: Metronomic  VS. MTD chemotherapy.  Alternative dosing and scheduling is 
expected to achieve higher antiproliferative efficacy via novel mechanisms of action 
such as anti-angiogenic effect, action on cancer stem cells or immuno-stimulating 
properties, in addition to direct cytotoxicity on tumor cells.   
 
Figure 2: Left: Skipper-Schabel-Wilcox log-kill model. Tumor growth is 
exponential (linear in log-scale) and each cycle of chemotherapy results in removal of 
a constant fraction of the tumor volume (as opposed to a constant amount of cells). 
This is reflected by a constant log-kill. The simulation assumes a log-kill of three (i.e. 
reduction of 99.9% of the tumor mass) over six three-weeks cycles, for an initial total 
tumor load of 10
9 
cells. The dashed line represents the size of one cell, that classical 
MTD chemotherapy approaches consider as the goal to achieve for eradication of the 
disease. Right: Norton-Simon model. Untreated tumor growth is Gompertzian and 
exhibits a decreasing specific growth rate. The Norton-Simon hypothesis implies a 
larger log-kill for smaller tumors and suggests to densify the chemotherapy 
administration protocol. This is illustrated by comparison of a three-weeks regimen 
(black curve) and a densified two-weeks regimen (grey curve). The latter exhibits 
deeper drop of the tumor burden and thus larger probability of “cure”. However, note 
that when tumor regrows, both schedules have the same time to recurrence. 
 
Figure 3: MTD vs Metronomic. Simulations of a mathematical model for the anti-
angiogenic effect of metronomic therapy for Docetaxel [44]. The MTD schedule is 
defined by 100 mg/m
2
 on the first day of a 21-days cycle. The metronomic schedule is 
defined by 10 mg/m
2
 daily with no drug-free breaks. Left: tumor volume. Right: 
carrying capacity, assumed to represent the vasculature. Despite initial superiority of 
the MTD regimen during the first cycles, on the long run the metronomic regimen 
achieves better tumor control. This is due to the intrinsically fast dynamics of the 
18 
endothelium that recovers during drug free intervals with the MTD schedule (right 
panel).
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